NewAmsterdam Pharma Company N.V. (NAMS) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Naarden, Netherlands. Le PDG actuel est Michael Harvey Davidson Facp..
NAMS a date d'introduction en bourse 2021-02-09, 68 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $3.91B.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands, dedicated to developing treatments for metabolic diseases. The company's lead investigational candidate, obicetrapib, is a novel selective inhibitor of Cholesteryl Ester Transfer Protein (CETP) that has demonstrated clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) while substantially increasing high-density lipoprotein cholesterol (HDL-C). This dual mechanism addresses a significant unmet medical need in lipid management and cardiovascular disease prevention. NewAmsterdam is focused on advancing obicetrapib through clinical development to improve patient outcomes in metabolic disease populations.
